Altimmune director buys 5,000 company shares

Altimmune, Inc. director Wayne Pisano reported buying additional company stock.

Rhea-AI Filing Summary

Altimmune, Inc. director Wayne Pisano reported buying additional company stock. On January 8, 2026, he purchased 5,000 shares of Altimmune common stock at a price of $4.082 per share. After this transaction, he directly owns 13,498 shares of Altimmune common stock. This activity was disclosed in a Form 4 insider trading report filed for a single reporting person.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Pisano Wayne

Role Director

Bought 5,000 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001	5,000	$4.082	$20K

Holdings After Transaction: Common Stock, par value $0.0001 — 13,498 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Altimmune (ALT) disclose in this Form 4?

The filing reports that director Wayne Pisano bought 5,000 shares of Altimmune common stock on January 8, 2026.

At what price did the Altimmune director buy shares?

The director purchased the 5,000 shares of Altimmune common stock at a price of $4.082 per share.

How many Altimmune (ALT) shares does Wayne Pisano own after the transaction?

Following the reported purchase, Wayne Pisano beneficially owns 13,498 shares of Altimmune common stock.

Is the Altimmune insider ownership in this Form 4 direct or indirect?

The Form 4 shows the 13,498 shares are held with direct (D) ownership by the reporting person.

What type of security did the Altimmune insider purchase?

The insider acquired Common Stock, par value $0.0001, of Altimmune, Inc.

Who signed the Altimmune Form 4 insider trading report?

The report was signed by /s/ Gregory Weaver, as Attorney-in-Fact on January 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pisano Wayne

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	01/08/2026		P		5,000	A	$4.082	13,498	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gregory Weaver, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.